Advertisement

Meeting Coverage

2021 AAN Annual Meeting Kick-Off!

Due to the COVID-19 pandemic, the 2021 American Academy of Neurology Annual Meeting, the world’s premier neurology meeting, will be held in a fully virtual format from April 17-22. It will include: Over 90 expert-led CME...

Read More

AAN 2021: Dual Tasking In Patients With MS

Patients with MS may have difficulty performing double task (DT) while walking or causing interference. More research is needed in order to define the role of disability degree in the severity of the interference produced in the...

Read More

MET Kinase Inhibitors Vs Sunitinib For pRCC

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...

Read More

Outcomes Of First-Line Immuno-Oncology Combo in mRCC

Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...

Read More

Tivozanib In Patients With aRCC

TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. The TIVO-3 study enrolled subjects with mRCC who failed two or three prior systemic regimens, one of...

Read More

CLEAR Trial: Promising New Combination to Treat RCC

In the phase 3 multicenter, open-label, randomized CLEAR trial, lenvatinib in combination with pembrolizumab or everolimus demonstrated significant benefits over sunitinib in patients with advanced renal cell carcinoma (RCC)....

Read More
Advertisement